Jianzhong Zhang
Peking University People's Hospital
Emerging Leaders
not ranked
Current Leaders
#4441 pts
All-Time Leaders
#15,8617 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2017. 6 trials as lead/chair. How it works →
Trials led — by scientific impact
A Randomized, Double Blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CM310 in Patients With Moderate-to-severe Atopic Dermatitis
Phase 3CompletedKeymed Biosciences Co.Ltd
2
impact
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HB0017 Injection in Patients With Moderate to Severe Plaque Psoriasis
Phase 3RecruitingHuabo Biopharm Co., Ltd.
1
impact
China Atopic Dermatitis Registry Study: a Chinese Registry Study in Moderate-to-severe Atopic Dermatitis Patients Not Controlled by Topical Therapy
N/AUnknownPeking University People's Hospital
1
impact
A Randomized, Double-Blind, Multi-Center, Active-Controlled, Parallel-Group Phase III Clinical Study to Compare the Efficacy and Safety of Recombinant Anti-TNFα Human Monoclonal Antibody Injection (HLX03) and Adalimumab Injection (Humira®) in Patients With Moderate to Severe Plaque Psoriasis
Phase 3CompletedShanghai Henlius Biotech
1
impact
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
Phase 2CompletedInventisBio Co., Ltd
1
impact
A Randomized, Double Blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CM310 in Adolescent Patients With Moderate-to-severe Atopic Dermatitis
Phase 3CompletedKeymed Biosciences Co.Ltd
1
impact
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1 Antihistamines
Phase 3Not Yet RecruitingJemincare
0
impact
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Clinical Study to Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis
Phase 2Not Yet RecruitingZhejiang Kanova Biopharmaceutical Co., LTD
0
impact
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
Phase 2RecruitingKeymed Biosciences Co.Ltd
0
impact
An Open-Label, Multicenter Study to Evaluate Long-Term Safety and Efficacy of CM512 in Atopic Dermatitis Patients.
Phase 2RecruitingKeymed Biosciences Co.Ltd
0
impact
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial of Single and Multiple Doses of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
Phase 1CompletedBeijing Dayspring Pharmaceutical Technology Co., Ltd
0
impact
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate LNK01001 in Adults Subjects With Moderate to Severe Atopic Dermatitis.
Phase 3CompletedLynk Pharmaceuticals Co., Ltd
0
impact
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
Phase 2CompletedBeijing Dayspring Pharmaceutical Technology Co., LtdStudy Chair
0
impact
A Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of CM310 in Adolescent Patients With Atopic Dermatitis
Phase 3ActiveKeymed Biosciences Co.Ltd
0
impact
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis
Phase 3CompletedSimcere Pharmaceutical Co., Ltd
0
impact
A Multinational, Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Comparison Trial to Demonstrate the Superiority of 1% OPA-15406 Ointment to the Vehicle in Adult Patients With Atopic Dermatitis
Phase 3CompletedOtsuka Beijing Research Institute
0
impact
A Randomized, Double-Blind, Placebo-Controlled, Phase Ib Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of GR2002 Injection in Patients With Moderate to Severe Atopic Dermatitis
Phase 1UnknownGenrix (Shanghai) Biopharmaceutical Co., Ltd.
0
impact
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficiency and Safety of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis
Phase 2CompletedLynk Pharmaceuticals Co., Ltd
0
impact
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Adult Patients With Moderate to Severe Alopecia Areata
Phase 3CompletedSuzhou Zelgen Biopharmaceuticals Co.,Ltd
0
impact
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Different Dosing Regimens of HB0017 Injection in Patients With Moderate to Severe Plaque Psoriasis
Phase 2CompletedHuabo Biopharm Co., Ltd.
0
impact
A Phase Ⅲ Multicenter, Randomized, Double-blind, Placebo-controlled To Assess Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Phase 3CompletedTianjin Hemay Pharmaceutical Co., Ltd
0
impact
A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of KX-826 for Topical Use in Chinese Adult Male Patients With Androgenetic Alopecia (AGA)
Phase 3UnknownSuzhou Kintor Pharmaceutical Inc,
0
impact
A Phase II Clinical Study to Evaluate the Efficacy and Safety of KX-826 Tincture in the Treatment of Adult Male Androgenetic Alopecia (AGA) Patients in China
Phase 2CompletedSuzhou Kintor Pharmaceutical Inc,
0
impact